<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144208">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01223352</url>
  </required_header>
  <id_info>
    <org_study_id>AC-052-373</org_study_id>
    <nct_id>NCT01223352</nct_id>
  </id_info>
  <brief_title>Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension</brief_title>
  <acronym>FUTURE 3</acronym>
  <official_title>An Open-label, Prospective Multicenter Study to Assess the Pharmacokinetics, Tolerability, Safety and Efficacy of the Pediatric Formulation of Bosentan Two Versus Three Times a Day in Children With Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of AC-052-373 was to assess the pharmacokinetic (PK) profile of two
      dosing regimens of the pediatric formulation of bosentan in children with pulmonary arterial
      hypertension (PAH) &lt;12 years of age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Daily exposure [AUC(0-24c)] to bosentan</measure>
    <time_frame>At Week 4, after at least 2 weeks of stable study drug treatment</time_frame>
    <description>Daily exposure was measured by the area under the plasma concentration-time curve over a period of 24 hours [AUC(0-24)].
Concentrations of bosentan were measured directly in blood samples collected prior to study drug administration and up to 12 hours or up to 8 hours post-dose for the b.i.d and t.i.d. dosing regimen, respectively. AUC(0-24) was calculated as a multiple of AUCtau (i.e., the AUC over a dosing interval): AUCtau x 2 for the b.i.d. dosing regimen and AUCtau x 3 for the t.i.d. regimen. As the smallest dose unit was 8 mg (1/4 tablet), it was not possible to achieve the exact target dose of 2 mg/kg. Therefore, AUC(0-24) was corrected to 2 mg/kg (target dose) [AUC(0-24c)].</description>
  </primary_outcome>
  <other_outcome>
    <measure>Maximum plasma concentration [Cmaxc] of bosentan</measure>
    <time_frame>At Week 4, after at least 2 weeks of stable study drug treatment</time_frame>
    <description>Concentrations of bosentan were measured directly in blood samples collected prior to study drug administration and up to 12 hours or up to 8 hours post-dose for the b.i.d and t.i.d. dosing regimen, respectively.
The peak plasma concentration (Cmax) of bosentan was directly obtained from the measured plasma concentrations and was dose-corrected to the target dose of 2 mg/kg (Cmaxc).</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to reach Cmax [tmax] of bosentan</measure>
    <time_frame>At Week 4, after at least 2 weeks of stable study drug treatment</time_frame>
    <description>Concentrations of bosentan were measured directly in blood samples collected prior to study drug administration and up to 12 hours or up to 8 hours post-dose for the b.i.d and t.i.d. dosing regimen, respectively.
tmax was obtained directly from the measured plasma concentrations.</description>
  </other_outcome>
  <other_outcome>
    <measure>Daily exposure [AUC(0-24c)] to bosentan metabolites (Ro 478634, Ro 485033, Ro 641056)</measure>
    <time_frame>At Week 4, after at least 2 weeks of stable study drug treatment.</time_frame>
    <description>Concentrations of the metabolites were measured directly in blood samples collected prior to study drug administration and up to 12 hours or up to 8 hours post-dose for the b.i.d and t.i.d. dosing regimen, respectively. Daily exposure to the metabolites corresponds to the area under the concentration-time curve [AUC(0-24)] of the corresponding metabolite over a period of 24 hours, and was calculated in the same manner as the primary endpoint. AUC(0-24c) was corrected to 2 mg/kg (target dose) [AUC(0-24c)].</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in WHO functional class at end of study</measure>
    <time_frame>Baseline and end of study</time_frame>
    <description>Number of patients with improvement, worsening or no change in WHO functional class at end of study compared to baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in Global clincial impression scale (GCIS) at end of study</measure>
    <time_frame>Baseline and end of study</time_frame>
    <description>The GCIS is an assessment tool to rate the patient's current overall clinical condition (&quot;Very Good&quot;, &quot;Good&quot;, &quot;Neither Good or Bad&quot;, &quot;Bad&quot; and &quot;Very Bad&quot;). The assessment was performed both by the physician and the parents
/ legal representatives independently. Number of patients with clinical condition (as measured by the GCIS) considered as worsened, improved or unchanged are reported here</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with treatment-emergent liver function abnormalities</measure>
    <time_frame>From baseline up to 7 days after end of treatment</time_frame>
    <description>Number of patients with increase in alanine aminotransferase (ALT) and / or aspartate aminotransferase (AST) above 3 x ULN (upper limit of normal). The worst post-baseline value was considered.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with treatment-emergent hemoglobin abnormalities</measure>
    <time_frame>From baseline up to 7 days after end of treatment</time_frame>
    <description>Number of patients with marked hemoglobin decreases. The worst post-baseline value was considered.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Bosentan 2 mg/Kg t.i.d.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg/kg bosentan administered three times a day (morning, afternoon, evening) for a planned duration of 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bosentan 2 mg/Kg b.i.d.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg/kg bosentan administered twice daily (morning and evening) for a planned duration of 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bosentan</intervention_name>
    <description>32 mg quadrisected dispersible tablet. The dosage of bosentan (2 mg/Kg) was adjusted according to the patient's body weight at initiation of the study treatment. Dosage readjustment was permitted after 12 weeks of treatment.</description>
    <arm_group_label>Bosentan 2 mg/Kg b.i.d.</arm_group_label>
    <arm_group_label>Bosentan 2 mg/Kg t.i.d.</arm_group_label>
    <other_name>Tracleer</other_name>
    <other_name>ACT-050088</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. PAH diagnosis confirmed with right heart catheterization (RHC):

               -  Idiopathic or heritable PAH, or

               -  Associated PAH persisting after complete repair of a congenital heart defect
                  (PAH has to be persistent for at least 6 months after surgery) or

               -  PAH-CHD associated with systemic-to-pulmonary shunts (after global amendment
                  dated 09 May 2012)

          2. WHO functional Class I, II or III

          3. Male or female ≥ 3 months and &lt; 12 years of age (maximum age at randomization is 11.5
             years)

          4. Body weight ≥ 3.5 kg

          5. Peripheral oxygen saturation (SpO2) ≥ 88% (at rest, on room air)

          6. Baseline PAH-therapy (Calcium channel blocker, bosentan, prostanoid, PDE-5 inhibitor)
             if present, has to be stable for at least 3 months prior to screening. During the
             study, all background treatments should remain stable

          7. Signed informed consent by the parents or legal representatives

        Exclusion Criteria:

          1. PAH etiologies other than listed above

          2. Non-stable disease status

          3. Need or plan to wean patient from intravenous epoprostenol or intravenous or inhaled
             iloprost

          4. Systolic blood pressure &lt; 80% of the lower limit of normal range

          5. AST and/or ALT values &gt; 1.5 times the upper limit of normal range.

          6. Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C

          7. Hemoglobin and/or hematocrit levels &lt; 75% of the lower limit of normal range.

          8. Known intolerance or hypersensitivity to bosentan or any of the excipients of the
             dispersible Tracleer tablet

          9. Treatment with forbidden medication within 2 weeks or at least 5 times the half-life
             prior to randomization, whichever is the longest:

               -  Glibenclamide (glyburide)

               -  Cyclosporin A

               -  Sirolimus

               -  Tacrolimus

               -  Fluconazole

               -  Rifampicin (rifampin)

               -  Ritonavir

               -  Co-administration of CYP2C9 inhibitors (e.g., amiodarone, voriconazole) and
                  moderate/strong CYP3A4 inhibitors (e.g., amprenavir, erythromycin, ketoconazole,
                  diltiazem, itraconazole)

               -  Endothelin receptor antagonists (ERAs) other than bosentan

         10. Treatment with another investigational drug within 1 month prior to randomization or
             planned treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andjela Kusic-Pajic, MD</last_name>
    <affiliation>Actelion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Children's Hospital - Site 9102</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center - Site 9104</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center Children's Hospital of New York Presbyterian - Site 9101</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital - Department of Cardiology - Site 9107</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital - Site 9106</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital Melbourne, Cardiology - Site 5001</name>
      <address>
        <city>Parkville</city>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Republican Scientific-Practical Center &quot;Cardiology&quot; - Site 3001</name>
      <address>
        <city>Minsk</city>
        <zip>220036</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital, Capital Medical University- Department of Pediatric Cardiology - Site 5103</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute and Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China 2nd university Hospital-Center of interventional diagnosis and therapy for Children's cardiovascular disease - Site 5104</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital - Site 5105</name>
      <address>
        <city>Guangdong</city>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Children's Medical Center - Site 5102</name>
      <address>
        <city>Shanghai</city>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital, Department of Pulmonary Circulation - Site 5101</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice v Motole, dětské kardiocentrum - Site 3301</name>
      <address>
        <city>Prague</city>
        <zip>150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Necker-Enfants Malades, Service de Cardiologie Pédiatrique - Site 2201</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Hôpital des Enfants, Service de Cardiologie Pédiatrique - Site 2202</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Kinderkardiologie - Site 1401</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn Abteilung für Kinderkardiologie - Site 1404</name>
      <address>
        <city>Bonn</city>
        <zip>53113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Justus-Liebig-Universität Giessen, Kinderherzzentrum - Site 1403</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gottsegen György Országos Kardiológiai Intézet, Gyermekszív Központ, Gyermek Kardiológiai osztály - Site 3401</name>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudományegyetem ÁOK Szent-Györgyi Albert Klinikai Központ, Gyermekgyógyászati Klinika és Gyermekegészségügyi Központ - Site 3402</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CARE Hospitals, Cardiology Dep. Hyderabad - Site 5302</name>
      <address>
        <city>Hyderabad</city>
        <zip>500001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indraprashta Apollo Hospitals, Pediatric Cardiology - Site 5303</name>
      <address>
        <city>New Dehli</city>
        <zip>110076</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Medical Center- Institute of pediatric cardiology - Site 7101</name>
      <address>
        <city>Petach Tikvah</city>
        <zip>49202</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Degli Studi di Padova - Dipartimento di Pediatria - Servizio di Cardiologia Pediatrica - Site 1501</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico &quot;Bambino Gesù&quot; - Dipartimento Medico Chirurgico di Cardiologia Pediatrica - Site 1502</name>
      <address>
        <city>Rome</city>
        <zip>00193</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cardiologia (INC) Ignacio Chavez - Site 8401</name>
      <address>
        <city>Mexico City</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Investigacion Clinica en Medicina, SC (UDICEM) - Site 8402</name>
      <address>
        <city>Monterrey</city>
        <zip>64710</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medish Centrum Groningen, Kindercardiologie - Site 1601</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne Klinika Kardiologii Dziecięcej i Wad Wrodzonych Serca - Site 3604</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Centrum Zdrowia Matki Polki Klinika Kardiologii ICMP w Lodz - Site 3602</name>
      <address>
        <city>Lodz</city>
        <zip>93-336</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Pomnik - Centrum Zdrowia Dziecka Klinika Kardiologii Dziecięcej - Site 3601</name>
      <address>
        <city>Warszawa</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny we Wrocławiu Oddział Kardiologii Dziecięcej z pododdziałem Intensywnego Nadzoru Kardiologicznego - Site 3605</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RAMS Institution, Research Institute for complex issues of cardiovascular diseases, Siberian branch of the Russian Academy of Medical Sciences - Site 3805</name>
      <address>
        <city>Kemerovo</city>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Center of Cardiovascular Surgery named after A.N.Bakulev of the RAMS - Site 3803</name>
      <address>
        <city>Moscow</city>
        <zip>121552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Scientific Research Institute for Pediatrics and Childrens Surgery of Rosmedtechnologies - Site 3804</name>
      <address>
        <city>Moscow</city>
        <zip>125412</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution &quot;Federal center of Heart, Blood and Endocrinology named after V.A.Almazov Rosmedtekhnologies&quot; - Site 3802</name>
      <address>
        <city>St. Petersberg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education &quot;Saint Petersburg State Pediatric Medical Academy of Roszdrav&quot; - Site 3801</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194100</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerzitetska dečja klinika, Služba za kardiologiju - Site 3901</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut za zdravstvenu zaštitu majke i deteta Srbije &quot;Dr Vukan Čupić&quot;, Služba za ispitivanje i lečenje bolesti srca i krvnih sudova - Site 3902</name>
      <address>
        <city>Belgrade</city>
        <zip>11070</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Paediatric Cardiology University of the Free State - Site 6001</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9300</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paediatric Cardiology Albert Luthuli Central Hospital - Site 6003</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Paediatric Cardiology, Steve Biko Academic Hospital - Site 6002</name>
      <address>
        <city>Pretoria</city>
        <zip>0001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitatario Vall d'Hebron, Neumologia - Site 1907</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz - Paediatric Cardiology Department - Site 1906</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Diagnostic Center - Pediatric Cardiovascular and ANES and Intensive Care Department - Site 4103</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49060</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gusak Ins Urgent and Recovery SUR AMS - Cardiovascular Rehabilitation Pediatric Department - Site 4101</name>
      <address>
        <city>Donetsk</city>
        <zip>83045</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gover INS - Scientific Practical Cardiovascular Pediatric Center - MOH Ukraine - Site 4102</name>
      <address>
        <city>Kiev</city>
        <zip>01135</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belarus</country>
    <country>China</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 2, 2016</lastchanged_date>
  <firstreceived_date>October 12, 2010</firstreceived_date>
  <firstreceived_results_disposition_date>August 22, 2014</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pulmonary arterial hypertension</keyword>
  <keyword>children</keyword>
  <keyword>pediatric</keyword>
  <keyword>bosentan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
